NCT01229540TerminatedNot Applicable
Clinical Research on Retinal Neovascularization of Diabetic Retinopathy
Tianjin Medical University1 site in 1 countryStarted: October 27, 2010Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Terminated
- Sponsor
- Locations
- 1
Study Overview
Brief Summary
Retinal neovascularization of diabetic retinopathy might be associated with genetic risk factors and environmental risk factors.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 45 Years to 74 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •T2DM was diagnosed according to the World Health Organization Expert Consultation Report 1999 and consisted of one of the following: fasting blood glucose (FBG) ≥7.0 mmol/L (≥126 mg/dL), blood glucose ≥11.1 mmol/L (≥200 mg/dL) 2 hours after an oral glucose tolerance test (OGTT); or a random blood glucose ≥11.1 mmol/L (≥200 mg/dL).
- •DR was clinically graded in accordance with the International Clinical Diabetic Retinopathy guidelines based on fundus fluorescence angiography.
- •All participants with PDR underwent a comprehensive dilated fundus examination to detect DR by indirect ophthalmoscopy and were diagnosed by fundus fluorescence angiography.
Exclusion Criteria
- •Patients were excluded if they had acute complications of diabetes mellitus, type 1 diabetes mellitus, other types of diabetes, serious cardiovascular, hepatic, nephritic or other complications, other serious primary diseases or mental illness.
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Not Applicable
A Study on the Treatment Strategy of NVG Secondary to PDRNeovascular GlaucomaProliferative Diabetic RetinopathyNCT05156021Ruijin Hospital39
Completed
Not Applicable
Incidence of Retinopathy and Associated Risk Factors in Children and Young Adults With Type 1 Diabetes in DenmarkType 1 DiabetesDiabetic RetinopathyNCT01785667Odense University Hospital132
Completed
Early Phase 1
Vascular Remodeling and the Effects of Angiogenic Inhibition in Diabetic RetinopathyDiabetic RetinopathyNCT00411333National Eye Institute (NEI)100
Completed
Phase 1
Ranibizumab for Treatment of Persistent Diabetic Neovascularization Assessed by Wide-Field ImagingProliferative Diabetic RetinopathyNCT00606138Rush University Medical Center9
Not yet recruiting
Not Applicable
Exploring the Interaction Between Metabolic Disorders and NLPR3 Inflammasome Activation in DR Inflammatory DamageDiabetic Macular EdemaAnti-vascular Endothelial Growth FactorDiabetic RetinopathyNCT06272565Zhongshan Ophthalmic Center, Sun Yat-sen University240
